2024 Vktx nasdaq - Find real-time VKTX - Viking Therapeutics Inc stock quotes, company profile, news and forecasts from CNN Business.

 
May 18, 2023 · NASDAQ: VKTX Viking Therapeutics. Market Cap. $1B. Today's Change (-2.28%) -$0.28. ... (VKTX-2.28%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's ... . Vktx nasdaq

Dec 4, 2023 · Viking Therapeutics Inc (NASDAQ:VKTX)’s Major holders. Insiders own 5.89% of the company shares, while shares held by institutions stand at 68.75% with a share float percentage of 73.05%. Investors are also buoyed by the number of investors in a company, with Viking Therapeutics Inc having a total of 246 institutions that hold shares in the ... Rhumbline Advisers acquired a new position in Viking Therapeutics, Inc. (NASDAQ:VKTX – Free Report) during the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 127,829 shares of the biotechnology company’s stock, valued at approximately $2,072,000. Rhumbline …At Stock Options Channel, our YieldBoost formula has looked up and down the VKTX options chain for the new August 11th contracts and identified one put and one call contract of particular interest ...Dec 4, 2023 · The public float for VKTX is 89.39M and currently, short sellers hold a 18.98% ratio of that float. The average trading volume of VKTX on December 04, 2023 was 2.05M shares. VKTX) stock’s latest price update. Viking Therapeutics Inc (NASDAQ: VKTX)’s stock price has plunge by 9.99relation to previous closing price of 13.01. Viking Therapeutics Inc (NASDAQ:VKTX) Viking Therapeutics Inc. 13.01. Delayed Data. As of Dec 01. +0.79 / +6.42%. Today’s Change. 3.54. Today ||| 52-Week Range. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today ...Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.He does not neglect the obesity-centered candidate VK2735, however, and writes, “We view VKTX’s lead candidate THR-β agonist VK2809 for NASH as similar to Madrigal Pharmaceutical’s MGL-3196 ...Madrigal Pharmaceuticals, Inc. Common Stock (MDGL) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.Apr 4, 2023 · Find out why VKTX stock is a Buy. ... (NASDAQ:VKTX). As you know, Viking shares recently rallied over 60% in a single trading session due to its positive early obesity data. Though Viking executed ... In a report released yesterday, Naz Rahman from Maxim Group maintained a Buy rating on Viking Therapeutics (VKTX – Research Report), with a price target of $35.00.The company’s shares opened ...NASDAQ: $115: $15 - $17 7,187,500: Goldman Sachs Cowen & Company: Preclinical biotech developing kinase inhibitors for cancer and genetic diseases. CoLucid Pharmaceuticals Burlington, MA: CLCD ...VKTX-3.57%. MDGL -0.85%. SPX-0.20% ... Real-time last sale data for U.S. stock quotes reflect trades reported through Nasdaq only. Intraday data delayed at least 15 minutes or per exchange ...Here's why they chose Bluebird Bio (NASDAQ: BLUE), Travere Therapeutics (NASDAQ: TVTX), and Viking Therapeutics (NASDAQ: VKTX). The upside is huge, but beware of the risks .VKTX: Viking Therapeutics broker recommendation chart. Get the latest chart with broker recommendations from Zacks Investment Research. ... NASDAQ data is at least 15 minutes delayed.Nasdaq +78.81(+0.55%) Russell 2000 1,862.64 +53.62(+2.96%) Crude Oil 74.38 -1.58(-2.08%) Gold 2,091.70 +34.50(+1.68%) Advertisement Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real... Next on this list of stocks that analysts love is Viking Therapeutics (NASDAQ: VKTX ). The stock has been rated by 11 analysts in the last three months with 10 of them giving VKTX stock a Strong ...Viking Therapeutics, Inc. (NASDAQ:VKTX) is a San Diego, California-based biotech company developing therapeutics for patients that are suffering from endocrine and metabolic disorders.Mar 29, 2023 · Viking Therapeutics (VKTX 4.42%), a small-cap biotech, has been on quite the ride over the past few months.Thanks to a positive late-stage trial in nonalcoholic steatohepatitis (NASH) from rival ... Find the latest press releases from Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com. Shares of Viking Therapeutics (NASDAQ: VKTX) are trading down over 15% late into Tuesday's session, in a move linked to the disappointing clinical data posted by VKTX's competitor Altimmune, Inc ...Find the latest Insider Activity data for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com. Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. Return. ... VKTX. $12.01 (-2.24%) $0.28 *Average returns of all recommendations since inception. Cost basis and ...Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, …Average portfolio weight of all funds dedicated to VKTX is 0.08%, an increase of 397.78%. Total shares owned by institutions increased in the last three months by 28.17% to 35,133K shares.Find out why VKTX stock is a Buy. ... (NASDAQ:VKTX). As you know, Viking shares recently rallied over 60% in a single trading session due to its positive early obesity data. Though Viking executed ...He does not neglect the obesity-centered candidate VK2735, however, and writes, “We view VKTX’s lead candidate THR-β agonist VK2809 for NASH as similar to Madrigal Pharmaceutical’s MGL-3196 ...Find the latest dividend history for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.Fintel reports that on May 3, 2023, Roth MKM maintained coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation.. Analyst Price Forecast Suggests 31.63% Upside. As of April 24 ...For Viking Therapeutics (NASDAQ: VKTX) that’s exactly what investors get. VKTX has currently five drugs in its development pipeline. Those drugs are targeting a variety of diseases including ...Nike, Inc. has no single specific owner. According to Nasdaq, the company is a publicly traded one, with its shares listed on the New York Stock Exchange under the symbol NKE. As of May, 2014, 83.29 percent of Nike’s shares were owned by in...Viking Therapeutics Inc. (VKTX) is an innovative biotechnology company developing novel therapeutics for metabolic and endocrine diseases. Metabolic and rare disease programs include novel selective thyroid... VKTX : 12.28 (+6.23%) Viking Therapeutics to Participate at Upcoming Investor Conferences PR Newswire - Thu Sep 7, 3:05PM CDT.Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, …Strong Quarter-End Cash Position of $393M. SAN DIEGO, July 26, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the ...Get the latest Madrigal Pharmaceuticals Inc (MDGL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions.May 16 (Reuters) - Viking Therapeutics Inc VKTX.O said on Tuesday its experimental drug, VK2809, met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease.Weight-loss medicines are rising in popularity. According to some estimates, this market will be worth $44 billion in risk-adjusted sales by 2030, while it was only valued at $2.5 billion last ...May 16 (Reuters) - Viking Therapeutics Inc VKTX.O said on Tuesday its experimental drug, VK2809, met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease.Nasdaq Composite Stock Market Premium Services. Stock Advisor. Our Flagship Service. Return. ... VKTX. $12.01 (-2.24%) $0.28 *Average returns of all recommendations since inception. Cost basis and ...The Viking Therapeutics stock price gained 0.94% on the last trading day (Wednesday, 29th Nov 2023), rising from $11.72 to $11.83. During the last trading day the stock fluctuated 4.26% from a day low at $11.74 to a day high of $12.24. The price has been going up and down for this period, and there has been a 5.91% gain for the last 2 weeks.NASDAQ: $115: $15 - $17 7,187,500: Goldman Sachs Cowen & Company: Preclinical biotech developing kinase inhibitors for cancer and genetic diseases. CoLucid Pharmaceuticals Burlington, MA: CLCD ...The Viking Therapeutics stock price gained 0.94% on the last trading day (Wednesday, 29th Nov 2023), rising from $11.72 to $11.83. During the last trading day the stock fluctuated 4.26% from a day low at $11.74 to a day high of $12.24. The price has been going up and down for this period, and there has been a 5.91% gain for the last 2 weeks.Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 13.01 +0.79 (+6.46%) At close: 04:00PM EST 13.10 +0.09 (+0.69%) After hours: 07:47PM EST...Fintel reports that on May 16, 2023, Oppenheimer maintained coverage of Viking Therapeutics (NASDAQ:VKTX) with a Outperform recommendation.. Analyst Price Forecast Suggests 35.91% Upside. As of ...Price Volume Sep '23 Oct '23 Nov '23 Dec '23 $10 $8 $12 $14 $16 $18 0M 10M 20M 2020. Display Events. Dividends. Splits. Earnings. News. Chart Style. Line. Mountain.Find the latest Viking Therapeutics, Inc. (VKTX) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors. ... Nasdaq 14,305.03 +78.83 ...Fintel reports that on May 16, 2023, BTIG maintained coverage of Viking Therapeutics (NASDAQ:VKTX) with a Buy recommendation.. Analyst Price Forecast Suggests 35.91% Upside. As of May 11, 2023 ...Dec 1, 2023 · View Viking Therapeutics, Inc VKTX investment & stock information. Get the latest Viking Therapeutics, Inc VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. SAN DIEGO, Sept. 11, 2017 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for ...The Nasdaq Composite is one of the most followed stock market indices in America. It’s also a volatile one, having tumbled 33% in 2022. But in 2023, it’s making a comeback. We are less than three months into the year, and the Nasdaq Composite has already surged 12%. CNBC’s Jim Cramer sees further opportunity in the tech-heavy …Mar 29, 2023 · Viking Therapeutics (VKTX 4.42%), a small-cap biotech, has been on quite the ride over the past few months.Thanks to a positive late-stage trial in nonalcoholic steatohepatitis (NASH) from rival ... Курс акций Viking Therapeutics Inc (VKTX). NASDAQ: VKTX. Покупаете или продаете акции, которые котируются в валюте, отличной от местной?NASDAQ:VKTX 13.01. 0.79 (6.46%) 1d Financials Technical Analysis 1w 1m 6m 1y Interactive chart Dec 1, 2023, 9:00 pm 0 This is a Panic-proof Portfolio opinion which is available only for Premium members Curated by Michael O'Reilly since 2020. 1550+ opinions with 4.81 rating (one of ...In the last 3 months, 9 analysts have offered 12-month price targets for Viking Therapeutics. The company has an average price target of $33.0 with a high of $40.00 and a low of $24.00. Below is a ...Viking Therapeutics last announced its quarterly earnings data on October 25th, 2023. The biotechnology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by $0.01. Viking Therapeutics has generated ($0.93) earnings per share over the last year ( ($0.93) diluted earnings per share).Viking Therapeutics, Inc ( NASDAQ: VKTX ), a clinical-stage biopharmaceutical firm developing treatments for metabolic and endocrine disorders, plans to raise $55.0 million in its upcoming IPO ...Oppenheimer analyst Jay Olson maintained a Buy rating on Viking Therapeutics ( VKTX – Research Report) yesterday and set a price target of $40.00. The company’s shares closed yesterday at $24. ...Viking Therapeutics Stock Price, News & Analysis (NASDAQ:VKTX) $13.01 +0.79 (+6.46%) (As of 12/1/2023 ET) Today's Range $11.82 $13.10 50-Day Range $9.24 …Average portfolio weight of all funds dedicated to VKTX is 0.08%, an increase of 365.99%. Total shares owned by institutions increased in the last three months by 26.65% to 35,130K shares.For Viking Therapeutics (NASDAQ: VKTX) that’s exactly what investors get. VKTX has currently five drugs in its development pipeline. Those drugs are targeting a variety of diseases including ...Indeed, Viking Therapeutics (NASDAQ:VKTX) stock is up 246% in the last year, providing strong gains for shareholders. Nonetheless, only a fool would ignore the risk that a loss making company ...VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 83% based on the firm’s underlying fundamentals and the stock ...That's the story for Viking Therapeutics ' ( VKTX 6.46%) share price so far this year. The stock jumped nearly 26% year to date by early March. It subsequently gave up all of those gains and then ...March 29, 2023 at 11:12 AM · 4 min read. Shares of Viking Therapeutics VKTX have surged almost 70% on Mar 28, after it announced positive clinical data of VK2735, a novel dual agonist of the ...Find the latest on short interest for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.Viking Therapeutics (NASDAQ:VKTX) Insider Buying and Selling Activity. Current Insider Ownership Percentage 4.40%. Number Of Insiders Buying (Last 12 Months) 0. Number Of Insiders Selling (Last 12 Months) 5. Amount Of Insider Selling (Last 12 Months) $14.60 M. Get VKTX Insider Trade Alerts.Viking Therapeutics (NASDAQ: VKTX) is one of the more exciting biopharma stocks out there. The firm is developing novel therapies to address endocrine and metabolic disorders. It has more than ...VKTX VKTX AFTER HOURS QUOTE VKTX LATEST AFTER HOURS TRADES. ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, ... Find the latest Earnings Report Date for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.Viking Therapeutics, Inc. (NASDAQ:VKTX) is a San Diego, California-based biotech company developing therapeutics for patients that are suffering from endocrine and metabolic disorders.Back to VKTX Overview About Latest Pre-Market Trades Nasdaq provides market information before market opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day.As of February 3, 2023, the average one-year price target for Viking Therapeutics is $18.70. The forecasts range from a low of $11.11 to a high of $31.50. The average price target represents an ... View real-time VKTX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...Viking Therapeutics Inc ( NASDAQ:VKTX) reported a strong quarter-end cash position of $376M. The company's net loss for Q3 2023 was $22.5 million, or $0.23 per share, compared to a net loss of $15 ...Dec 4, 2023 · Shares of Viking Therapeutics, Inc. (NASDAQ:VKTX – Get Free Report) have received an average rating of “Buy” from the nine analysts that are presently covering the stock, MarketBeat Ratings reports. Nine analysts have rated the stock with a buy recommendation. The average 12 month target price among brokers that have covered the stock in the […] Viking Therapeutics, Inc. Common Stock (VKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83.Oppenheimer analyst Jay Olson maintained a Buy rating on Viking Therapeutics ( VKTX – Research Report) yesterday and set a price target of $40.00. The company’s shares closed yesterday at $24. ...NASDAQ: VKTX Viking Therapeutics. Market Cap. $1B. Today's Change (1.85%) $0.21. Current Price. $11.56. ... (VKTX 1.85%) are down about 25% from the peak they reached in mid-March. If you weren't ...Viking Therapeutics' (NASDAQ:VKTX) shares rose 14% after clinical results from a Phase 1 trial on its obesity drug, VK2735, were released. The study showed that VK2735, a dual agonist of GLP-1 and ...VFS. VinFast Auto Ltd. Ordinary Shares. $17.15 -0.84 -4.67%. Find the latest news headlines from Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.Here's why they chose Bluebird Bio (NASDAQ: BLUE), Travere Therapeutics (NASDAQ: TVTX), and Viking Therapeutics (NASDAQ: VKTX). The upside is huge, but beware of the risks .EPS Estimate Trends. Current. N/A. 1 Month Ago. -$0.24. 3 Months Ago. -$0.24. Viking Therapeutics Inc. analyst estimates, including VKTX earnings per share estimates and analyst recommendations.A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. VKTX shares currently have a short interest ratio of 9.0. Learn More on Viking Therapeutics's short interest ratio.VKTX Stock 12 Months Forecast. $34.00. (187.40% Upside) Based on 6 Wall Street analysts offering 12 month price targets for Viking Therapeutics in the last 3 months. The average price target is $34.00 with a high forecast of $40.00 and a low forecast of $28.00. The average price target represents a 187.40% change from the last price of $11.83. VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 83% based on the firm’s underlying fundamentals and the stock ...About Institutional Holdings. Nasdaq provides the ownership stake information in a company, including the number of shares held by those institutions in a firm, along with recent purchases and ... Below is Validea's guru fundamental report for VIKING THERAPEUTICS INC (VKTX). Of the 22 guru strategies we follow, VKTX rates highest using our Quantitative Momentum Investor model based on the ...Viking Therapeutics' (NASDAQ:VKTX) shares rose 14% after clinical results from a Phase 1 trial on its obesity drug, VK2735, were released. The study showed that VK2735, a dual agonist of GLP-1 and ...Vktx nasdaq

If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can.... Vktx nasdaq

vktx nasdaq

Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) Q2 2023 Earnings Conference Call July 26, 2023 4:30 PM ETCompany ParticipantsStephanie Diaz - Manager of...Since the year began, shares of Viking Therapeutics (NASDAQ:VKTX) exploded from about $8 to about $25 a share.All thanks to its potential treatment for obesity, VK2735. So far, we know it works ...Viking Therapeutics, Inc. (VKTX-NASDAQ) announced the presentation of data from a proof of concept a 35.7% mean reduction in liver weight. The company is On September 11, 2017, Viking announced positive results from clinical trial of patients with Current Price (09/12/17) $1.16 Valuation $7.00 OUTLOOK SUMMARY DATA Risk Level …Nov 29, 2023 · Real time Viking Therapeutics (VKTX) stock price quote, stock graph, news & analysis. NASDAQ Stock VKTX - Share Viking Therapeutics, Inc. trades in NASDAQ under Health Care Deals in Major Pharmaceuticals. These tomorrow's movement predictions & forecast of Viking Therapeutics, Inc. (VKTX) are just for tomorrow's session.Mar 29, 2023 · Shares of Viking Therapeutics VKTX have surged almost 70% on Mar 28, after it announced positive clinical data of VK2735, a novel dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose ... VKTX Price Action: Viking Therapeutics is making new 52-week highs on Monday. The stock was up 46.2% at $5.88 at time of publication, according to Benzinga Pro. Photo: Konstantin Kolosov from Pixabay.Get the latest Viking Therapeutics, Inc VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more. ... NASDAQ data is at least 15 minutes delayed.He does not neglect the obesity-centered candidate VK2735, however, and writes, “We view VKTX’s lead candidate THR-β agonist VK2809 for NASH as similar to Madrigal Pharmaceutical’s MGL-3196 ...Jun 11, 2021 · Viking Therapeutics Inc (Symbol: VKTX) saw options trading volume of 5,067 contracts, representing approximately 506,700 underlying shares or approximately 53.5% of VKTX's average daily trading ... Nov 21, 2023 · VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 55% based on the firm’s underlying fundamentals and the stock ... VFS. VinFast Auto Ltd. Ordinary Shares. $17.15 -0.84 -4.67%. Find the latest news headlines from Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com. May 16, 2023 · May 16 (Reuters) - Viking Therapeutics Inc VKTX.O said on Tuesday its experimental drug, VK2809, met the main goal of a mid-stage trial to treat patients with a type of fatty liver disease. With ... EPS Estimate Trends. Current. N/A. 1 Month Ago. -$0.24. 3 Months Ago. -$0.24. Viking Therapeutics Inc. analyst estimates, including VKTX earnings per share estimates and analyst recommendations.As of February 3, 2023, the average one-year price target for Viking Therapeutics is $18.70. The forecasts range from a low of $11.11 to a high of $31.50. The average price target represents an ... Simply Wall St ™. Simply Wall Street Pty Ltd. Level 7, 320 Pitt Street, Sydney. Popular Markets. US AU UK IN CA ZA. About Us Careers. Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927).Viking Therapeutics (NASDAQ:VKTX) Insider Buying and Selling Activity. Current Insider Ownership Percentage 4.40%. Number Of Insiders Buying (Last 12 Months) 0. Number Of Insiders Selling (Last 12 Months) 5. Amount Of Insider Selling (Last 12 Months) $14.60 M. Get VKTX Insider Trade Alerts.If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...Viking Therapeutics (NASDAQ: VKTX) is one of the more exciting biopharma stocks out there. The firm is developing novel therapies to address endocrine and metabolic disorders. It has more than ...Feb 9, 2023 · Viking Therapeutics, Inc. (NASDAQ:NASDAQ:VKTX) Q4 2022 Results Conference Call February 8, 2023 4:30 AM ETCompany ParticipantsStephanie Diaz - Investor... Average portfolio weight of all funds dedicated to VKTX is 0.08%, an increase of 397.78%. Total shares owned by institutions increased in the last three months by 28.17% to 35,133K shares.Based on analysts offering 12 month price targets for VKTX in the last 3 months. The average price target is $ 0.00 with a high estimate of $ 0.00 and a low estimate of $ 0.00 .Viking Therapeutics Announces Pricing of $250 Million Public Offering of Common Stock. SAN DIEGO , March 29, 2023 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic a... 8 months ago - PRNewsWire.Nasdaq +78.81(+0.55%) Russell 2000 1,862.64 +53.62(+2.96%) Crude Oil 74.38 -1.58(-2.08%) Gold 2,091.70 +34.50(+1.68%) Advertisement Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real...Viking Therapeutics (NASDAQ: VKTX) stock is climbing higher on Tuesday after initiating a Phase 1 clinical trial of VK2735. VK2735 is a dual glucagon-like peptide 1 (GLP-1) and “glucose ...Find the latest Insider Activity data for Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com. View real-time VKTX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: Includes ETFs & ETNs with ...The Nasdaq Composite ... (VKTX 6.23%), whose shares jumped 48%. Viking is looking at a NASH treatment that could use an approach similar to that of Madrigal's candidate, and while Viking's drug is ...Of the funds tracked by Insider Monkey, Peter S. Park's Park West Asset Management has the largest position in Viking Therapeutics, Inc. (NASDAQ:VKTX), worth close to $12 million, accounting for 0 ...May 11, 2023 · As of May 11, 2023, the average one-year price target for Viking Therapeutics is 29.89. The forecasts range from a low of 23.23 to a high of $36.75. The average price target represents an increase ... Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Viking Therapeutics Inc (Symbol: VKTX), where a total of 11,518 contracts have traded ...Viking Therapeutics last announced its earnings data on October 25th, 2023. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.01. Viking Therapeutics has generated ($0.93) earnings per share over the last year ( ($0.93) diluted earnings per …Viking Therapeutics, Inc. Common Stock (VKTX) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. On September 8, 2023, analysis has identified a bullish chart pattern known as the "Bottom Triangle" on Viking Therapeutics Inc (VKTX:NASDAQ). This bullish pattern suggests the potential for a ...Viking Therapeutics, Inc. (VKTX) NasdaqCM - NasdaqCM Real Time Price. Currency in USD Follow 2W 10W 9M 13.01 +0.79 (+6.46%) At close: 04:00PM EST 13.10 …Viking Therapeutics last announced its earnings data on October 25th, 2023. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.01. Viking Therapeutics has generated ($0.93) earnings per share over the last year ( ($0.93) diluted earnings per …Fintel reports that on April 25, 2023, Oppenheimer maintained coverage of Viking Therapeutics (NASDAQ:VKTX) with a Outperform recommendation.. Analyst Price Forecast Suggests 29.59% Upside. As of ...If you’re familiar with investing, then you’ve probably heard of major stock exchanges like the New York Stock Exchange or the NASDAQ. Stock exchanges are sort of like a mixture between an auction house and a marketplace where investors can...Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added ~39% pre-market Tuesday after announcing that its obesity candidate VK2735 led to an average body weight reduction of up to ~8% in a ...The 36-month beta value for VKTX is also noteworthy at 0.59. There are mixed opinions on the stock, with 10 analysts rating it as a “buy,” 1 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.” ... Viking Therapeutics Inc (NASDAQ: VKTX)’s stock price has plunge by 0.94relation to previous closing price ...26 jul 2023 ... PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of ...Price Volume Sep '23 Oct '23 Nov '23 Dec '23 $10 $8 $12 $14 $16 $18 0M 10M 20M 2020. Display Events. Dividends. Splits. Earnings. News. Chart Style. Line. Mountain.View real-time VKTX stock price and news, along with industry-best analysis. ... Nasdaq, NYSE American and NYSE Arca listings. Sources: FactSet, Dow Jones. ETF Movers: …Feb 28, 2023 · 3,698,369. 784,592. 4.713748. Back to VKTX Overview. NASDAQ, Inc. short interest is available by issuer for the past 12 months and updated twice a month. Short interest data is reported on mid ... Dec 1, 2023 · According to the issued ratings of 9 analysts in the last year, the consensus rating for Viking Therapeutics stock is Buy based on the current 9 buy ratings for VKTX. The average twelve-month price prediction for Viking Therapeutics is $30.25 with a high price target of $37.00 and a low price target of $19.00. VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 55% based on the firm’s underlying fundamentals and the stock ...Shares of the clinical-stage metabolic disorder specialist Viking Therapeutics ( VKTX -2.28%) were down by 6.45% on moderate volume as of 1:42 p.m. ET Thursday afternoon. The drugmaker's shares ...VKTX Latest Real Time Trades ... Add symbols now or see the quotes that matter to you, anywhere on Nasdaq.com. Start browsing stocks, funds and ETFs, and more asset classes. /Viking Therapeutics, Inc. (VKTX-NASDAQ) announced the presentation of data from a proof of concept a 35.7% mean reduction in liver weight. The company is On September 11, 2017, Viking announced positive results from clinical trial of patients with Current Price (09/12/17) $1.16 Valuation $7.00 OUTLOOK SUMMARY DATA Risk Level …About Latest Pre-Market Trades. Nasdaq provides market information opens daily from 4:15 A.M. ET to 7:30 A.M. ET on the following day. See Also. Nasdaq MarketSIte. Do Not Sell My Personal ... VKTX Overview Stock Screener Earnings Calendar Sectors Nasdaq | VKTX U.S.: Nasdaq Viking Therapeutics Inc. Watch NEW Set a price target alert After Hours Last Updated: Nov 20, 2023 7:59...Viking Therapeutics, Inc. Common Stock (VKTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.VKTX (U.S.: Nasdaq) Overview Profile FinancialsAs of February 3, 2023, the average one-year price target for Viking Therapeutics is $18.70. The forecasts range from a low of $11.11 to a high of $31.50. The average price target represents an ...The announcement has buoyed biotechs with oral weight loss candidates in development, such as Viking Therapeutics (NASDAQ:VKTX) and Structure Therapeutics (NASDAQ:GPCR).Market Cap. $1.3B. Currency in USD. Quote data delayed by at least 15 minutes. Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added ~39% pre-market Tuesday after announcing that its obesity candidate VK2735 led to an average body weight reduction of up to ~8% in a ...In the last 3 months, 9 analysts have offered 12-month price targets for Viking Therapeutics. The company has an average price target of $33.0 with a high of $40.00 and a low of $24.00. Below is a ...Find the latest press releases from Viking Therapeutics, Inc. Common Stock (VKTX) at Nasdaq.com.Below is Validea's guru fundamental report for VIKING THERAPEUTICS INC (VKTX). Of the 22 guru strategies we follow, VKTX rates highest using our Quantitative Momentum Investor model based on the ...For Viking Therapeutics (NASDAQ: VKTX) that’s exactly what investors get. VKTX has currently five drugs in its development pipeline. Those drugs are targeting a variety of diseases including ...Market Cap. $1.3B. Currency in USD. Quote data delayed by at least 15 minutes.May 11, 2023 · As of May 11, 2023, the average one-year price target for Viking Therapeutics is 29.89. The forecasts range from a low of 23.23 to a high of $36.75. The average price target represents an increase ... Shares of clinical-stage biotech Viking Therapeutics ( VKTX 6.68%) fell by as much as 4.8% on exceptionally low volume during the first hour of trading Tuesday morning. Since this mid-single-digit ...Of the funds tracked by Insider Monkey, Peter S. Park's Park West Asset Management has the largest position in Viking Therapeutics, Inc. (NASDAQ:VKTX), worth close to $12 million, accounting for 0 ...Viking Therapeutics, Inc. Common Stock (VKTX) Real-time Stock Quotes - Nasdaq offers real-time quotes & market activity data for US and global markets.XBI, IMGN, VKTX, TGTX: ETF Outflow Alert. Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR S&P Biotech ETF ...View Viking Therapeutics, Inc VKTX investment & stock information. Get the latest Viking Therapeutics, Inc VKTX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.He does not neglect the obesity-centered candidate VK2735, however, and writes, “We view VKTX’s lead candidate THR-β agonist VK2809 for NASH as similar to …Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added ~39% pre-market Tuesday after announcing that its obesity candidate VK2735 led to an average body weight reduction of up to ~8% in a ...Viking Therapeutics Inc (NASDAQ: VKTX) shares are trading higher Tuesday after the company presented new data from its Phase 2b studySVB Securities analyst Thomas Smith maintained a Buy rating on Viking Therapeutics (VKTX - Research Report) on October 26 and set a price target o... SVB Securities analyst Thomas Smith maintained a Buy rating on Viking Therapeutics (VKTX -...Viking Therapeutics last announced its earnings data on October 25th, 2023. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.22) by $0.01. Viking Therapeutics has generated ($0.93) earnings per share over the last year ( ($0.93) diluted earnings per …Viking Therapeutics, Inc. (NASDAQ:VKTX) is developing treatments for liver diseases, post surgical complications, and other ailments. Despite a hefty short interest percentage, the firm's shares ...Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.Viking Therapeutics (NASDAQ:VKTX) Insider Buying and Selling Activity. Current Insider Ownership Percentage 4.40%. Number Of Insiders Buying (Last 12 Months) 0. Number Of Insiders Selling (Last 12 Months) 5. Amount Of Insider Selling (Last 12 Months) $14.60 M. Get VKTX Insider Trade Alerts.Mar 19, 2023 · VIKING THERAPEUTICS INC ( VKTX) is a small-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 83% based on the firm’s underlying fundamentals and the stock ... Dec 1, 2023 · 9 brokers have issued 1 year target prices for Viking Therapeutics' shares. Their VKTX share price targets range from $19.00 to $37.00. On average, they predict the company's stock price to reach $30.25 in the next twelve months. This suggests a possible upside of 132.5% from the stock's current price. Turning to the calls side of the option chain, the call contract at the $17.00 strike price has a current bid of $3.50. If an investor was to purchase shares of VKTX stock at the current price ...NAV / 1-Day Return 392.46 / 0.42 %. Total Assets 2.7 Bil. Adj. Expense Ratio 0.080%. Expense Ratio 0.080%. Distribution Fee Level Low. Share Class Type Institutional. Category Large Blend ...Clinical-stage biotech Viking Therapeutics (NASDAQ:VKTX) added 15% on Monday after Roche (OTCQX:RHHBY) agreed to acquire a peer obesity drugmaker Carmot Therapeutics (CRMO) in a up to $3.1B deal ...Viking Therapeutics (NASDAQ: VKTX) stock is on the move Wednesday as the clinical-stage biopharmaceutical company reveals data from a clinical trial. This data comes from its Phase 1 study of .... Pdi stock forecast